Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib patient outreach program study in advanced or metastatic medullary thyroid cancer
2010-023428-26Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of vandetanib in Medullary Thyroid Cancer (MTC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Percentage of time with grade 2 or higher adverse events. Started Nov 2010; status: completed.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2010-023428-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023428-26.